Donor derived Mycobacterium tuberculosis infection after solid‐organ transplantation: A comprehensive review

Abstract

Background Mycobacterium tuberculosis may be transmitted via the allograft to cause a morbid and potentially fatal infection after solid organ transplantation (SOT). We reviewed all reported cases of donor‐derived tuberculosis (DDTB) to provide an update on its epidemiology, clinical course, and outcome after SOT. Methods MEDLINE, OVID, and EMBASE were reviewed from its inception until December 31, 2016 using key words donor‐derived infection, tuberculosis and solid organ transplant or transplantation. Results We retrieved 36 cases of proven (n = 17), probable (n = 8), and possible (n = 11) DDTB among 16 lung, 13 kidney, 6 liver, and 1 heart recipients. Most patients were male (21/35, 60%) with median age of 48 (range 23‐68) years. Median time to clinical presentation or diagnosis was 2.7 months (range 0.2‐29). The most common donor risk factor was residence in a TB‐endemic area (13/28, 46.4%). Fever was the most frequent presenting symptom (20/36, 56.5%). Diagnosis of tuberculosis was mostly made via AFB smear or mycobacterial culture (30/36, 83.3%). Allograft involvement was expectedly common; there were almost equal proportions of pulmonary (36%), extra‐pulmonary (28%) and disseminated (36%) cases. All cases of pulmonary TB were identified only among lung transplant recipients. The median duration of TB treatment was 10.5 (range 3‐24) months. Graft loss occurred in four (4/22, 18.2%) patients. All‐cause mortality was 25% (9/36); four of nine deaths were attributed to TB. Conclusions Donor‐derived TB presents early after SOT, most commonly as fever, and carries a high mortality risk. Donors should be screened, with particular attention to TB risk factors. Fever during the early post‐operative period should prompt a thorough evaluation for DDTB in endemic regions and among patients with “at‐risk” donors.